#United States #San Diego #Robbins LLP #Investor Rights #Capricor Therapeutics

Robbins LLP Brings Class Action Notice to Capricor Therapeutics Investors

In an important update for investors of Capricor Therapeutics, Inc., Robbins LLP has initiated a class action lawsuit, specifically targeting shareholders who acquired securities between October 9, 2024, and July 10, 2025. Capricor Therapeutics, a biotech company focused on innovative cell and exosome-based therapies for serious conditions like Duchenne muscular dystrophy (DMD), has recently been under scrutiny for its claims around the efficacy of its leading product, deramiocel.

Overview of Capricor Therapeutics and its Challenges

Capricor is at the forefront of developing therapies aimed at treating DMD, a severe genetic disorder that leads to muscle degeneration. The company’s cornerstone product, deramiocel, is derived from cardiosphere-derived cells and is touted as a breakthrough in the treatment landscape for DMD.

However, the recent timeline has posed significant questions about its therapeutic claims. According to allegations in the filed complaint, during the class period, Capricor’s leadership provided misleading information regarding deramiocel’s prospects, particularly its ability to gain FDA approval for treating cardiomyopathy associated with DMD. This has raised concerns among investors, leading to the current legal proceedings initiated by Robbins LLP.

Allegations of Deceptive Practices

The lawsuit highlights allegations that Capricor misrepresented key data regarding the safety and efficacy of deramiocel, particularly related to its Phase 2 HOPE-2 trial study. Claims were made suggesting that the drug was on the verge of receiving a crucial approval, all while critical safety and efficacy data were not disclosed or were downplayed. This lack of transparency led to a misguided confidence among investors, resulting in significant financial losses when the truth began to surface.

On July 11, 2025, Capricor disclosed that it received a Complete Response Letter (CRL) from the FDA, which explicitly stated that the submission for a Biologics License Application (BLA) did not meet the necessary standards for substantial evidence of effectiveness, calling for more clinical data and highlighting issues in the Chemistry, Manufacturing, and Controls areas of the application. This announcement caused Capricor's stock to plummet from $11.40 to $7.64 in just a matter of hours, marking a devastating setback for shareholders.

Investor Participation in the Class Action

For those affected by these developments, the class action lawsuit offers a potential avenue for compensation. Investors who wish to act as lead plaintiffs can contact Robbins LLP for guidance. It's significant to note that while participation in the lawsuit is encouraged, investors can still be considered as part of the class without active involvement in the legal action.

Robbins LLP operates on a contingency fee basis, meaning that shareholders won’t bear any upfront costs. This structure aims to broaden access to legal recourse for impacted investors, further ensuring that no fees are incurred unless there is a successful recovery.

About Robbins LLP

Established in 2002, Robbins LLP has built a robust reputation as a leader in shareholder rights litigation. The firm specializes in advocating for investors seeking to reclaim losses and improve corporate governance practices. Robbins LLP’s experienced team is dedicated to holding corporations accountable for misleading practices and ensuring that investor rights are not compromised.

For those looking to keep abreast of further developments regarding the class action against Capricor Therapeutics, or who want to sign up for alerts about corporate misconduct, Robbins LLP offers resources such as the Stock Watch program.

This situation underlines the pressing need for transparency within the biotechnology sector, especially when it concerns the treatment of severe medical conditions. As the case unfolds, shareholders of Capricor Therapeutics will be keenly watching how these legal proceedings progress, hopeful for a resolution that affirms investor rights and corporate accountability.